Home Cart Sign in  
Chemical Structure| 2095432-71-4 Chemical Structure| 2095432-71-4

Structure of GSK269962A HCl
CAS No.: 2095432-71-4

Chemical Structure| 2095432-71-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

GSK269962 HCl is a selective ROCK (Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively.

Synonyms: GSK269962 hydrochloride; GSK269962B; GSK269962

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of GSK269962A HCl

CAS No. :2095432-71-4
Formula : C29H31ClN8O5
M.W : 607.06
SMILES Code : O=C(NC1=CC=CC(OC2=CC3=C(N=C(C4=NON=C4N)N3CC)C=N2)=C1)C5=CC=C(OCCN6CCOCC6)C=C5.[H]Cl
Synonyms :
GSK269962 hydrochloride; GSK269962B; GSK269962
MDL No. :MFCD31536773
InChI Key :UYKVMFKKKLLDGL-UHFFFAOYSA-N
Pubchem ID :57398146

Safety of GSK269962A HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of GSK269962A HCl

cytoskeleton

Isoform Comparison

Biological Activity

Description
GSK269962A (GSK 269962) is a potent ROCK inhibitor, which effective against both ROCK1 and ROCK2 isoforms, with IC50 values of 1.6 and 4 nM, respectively. GSK269962A has anti-inflammatory and vasodilatory activities[1].
Target
  • ROCK1

    ROCK1, IC50:1.6 nM

  • ROCK2

    ROCK2, IC50:4 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
OCI-AML3 80 nM 72 hours Inhibited AML cell growth, induced G2 phase arrest and apoptosis Front Pharmacol. 2022 Dec 6;13:1064470.
MV4-11 80 nM 72 hours Inhibited AML cell growth, induced G2 phase arrest and apoptosis Front Pharmacol. 2022 Dec 6;13:1064470.
LepR+ MSCs 1 μM 48 hours Inhibition of ROCK1 signaling pathway, reducing the expression of fibrosis markers Col1a1, vimentin, and α-SMA Cell Commun Signal. 2024 May 6;22(1):257.
UACC62 625nM 48 hours To evaluate the effect of GSK269962A on the proliferation of MAPKi-resistant melanoma cells, showing complete inhibition of proliferation at 625nM concentration. bioRxiv [Preprint]. 2024 Jan 11:2024.01.09.574940.
M481 625nM 48 hours To evaluate the effect of GSK269962A on the proliferation of MAPKi-resistant melanoma cells, showing complete inhibition of proliferation at 625nM concentration. bioRxiv [Preprint]. 2024 Jan 11:2024.01.09.574940.
A375 625nM 48 hours To evaluate the effect of GSK269962A on the proliferation of MAPKi-resistant melanoma cells, showing complete inhibition of proliferation at 625nM concentration. bioRxiv [Preprint]. 2024 Jan 11:2024.01.09.574940.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOD-SCID/IL2Rgnull mice AML model Intraperitoneal injection 5 mg/kg and 10 mg/kg 5 days per week for 4 weeks Significantly prolonged mouse survival and reduced leukemia cell infiltration Front Pharmacol. 2022 Dec 6;13:1064470.
Mice PE-induced prostatic hyperplasia model Intraperitoneal injection 5 mg/kg Four times a week for four weeks GSK269962A reduces prostatic stromal hyperplasia and collagen deposition by inhibiting ROCK1 signaling pathway Cell Commun Signal. 2024 May 6;22(1):257.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.65mL

0.33mL

0.16mL

8.24mL

1.65mL

0.82mL

16.47mL

3.29mL

1.65mL

References

 

Historical Records

Categories